Business, energy, technology, markets and global industry news from Business News Today

Adbry

PharmaDeviceNews Adbry
Editorial infographic highlighting LEO Pharma’s 21 dermatology research posters covering Anzupgo, Spevigo and Adbry, featuring skin tissue illustrations, clinical research imagery and key highlights on adolescent FDA review, clinical evidence and commercial growth prospects.
Pharma & Biotech

Why LEO Pharma is investing in real-world evidence for difficult dermatological diseases

LEO Pharma presents 21 dermatology posters covering Anzupgo, Spevigo and Adbry. Examine adolescent FDA review, clinical data and growth prospects.

Read More
LEO Pharma’s 10% CER revenue growth, led by expanding dermatology brands including Anzupgo and Spevigo, comes as the company increases investment in its late-stage pipeline and rare skin disease portfolio. Representative image.
Pharma & Biotech

LEO Pharma’s sales engine is accelerating, but its next growth bet is already squeezing margins

LEO Pharma’s strategic brands are surging as dersimelagon expands its pipeline, but heavier investment is putting 2026 margins under pressure.

Read More
LEO Pharma’s TRAPEDS-1 trial evaluated the pharmacokinetics and long-term safety of tralokinumab in children with moderate-to-severe atopic dermatitis. Representative image.
Pharma & Biotech

LEO Pharma reports long-term pediatric tralokinumab safety findings from TRAPEDS-1

LEO Pharma’s TRAPEDS-1 data support pediatric tralokinumab development, but the small trial leaves efficacy and approval questions open.

Read More